GlaxoSmithKline market cap is £83.5 b, and annual revenue was £30.82 b in FY 2018

GlaxoSmithKline Gross profit (Q2, 2019)5.2 B

GlaxoSmithKline Gross profit margin (Q2, 2019), %66.2%

GlaxoSmithKline Net income (Q2, 2019)1.1 B

GlaxoSmithKline EBIT (Q2, 2019)1.5 B

GlaxoSmithKline Cash, 30-Jun-20194.1 B

GlaxoSmithKline EV112.8 B

GlaxoSmithKline revenue was £30.82 b in FY, 2018 which is a 2.1% year over year increase from the previous period.

GlaxoSmithKline revenue breakdown by business segment: 24.8% from Consumer Healthcare, 19.1% from Vaccines and 56.0% from Global Pharmaceuticals

GlaxoSmithKline revenue breakdown by geographic segment: 25.9% from Europe, 35.3% from International and 38.9% from US

GBP | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Revenue | 27.9b | 30.2b | 30.8b |

| 17% | 8% | 2% |

## Cost of goods sold | 9.3b | 10.3b | 10.2b |

## Gross profit | 18.6b | 19.8b | 20.6b |

| 67% | 66% | 67% |

## R&D expense | 3.6b | 4.5b | 3.9b |

## General and administrative expense | 9.4b | 9.7b | 9.9b |

## Operating expense total | 16.0b | 15.8b | 15.1b |

## EBIT | 2.6b | 4.1b | 5.5b |

| 9% | 14% | 18% |

## Interest expense | 736.0m | 734.0m | 798.0m |

## Interest income | 72.0m | 65.0m | 81.0m |

## Pre tax profit | 1.9b | 3.5b | 4.8b |

## Income tax expense | 877.0m | 1.4b | 754.0m |

## Net Income | 1.1b | 2.2b | 4.0b |

## EPS | 0.2 | 0.3 | 0.7 |

GBP | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
---|---|---|---|---|---|---|---|---|

## Revenue | 7.4b | 7.3b | 7.8b | 7.2b | 7.3b | 8.1b | 7.7b | 7.8b |

## Cost of goods sold | 2.5b | 2.6b | 2.7b | 2.4b | 2.3b | 2.6b | 2.7b | 2.6b |

## Gross profit | 4.9b | 4.7b | 5.2b | 4.8b | 5.0b | 5.5b | 4.9b | 5.2b |

| 66% | 64% | 66% | 67% | 68% | 67% | 64% | 66% |

## R&D expense | 960.0m | 1.3b | 1.0b | 904.0m | 925.0m | 988.0m | 1.0b | 1.1b |

## General and administrative expense | 2.5b | 2.4b | 2.3b | 2.3b | 2.5b | 2.5b | 2.5b | 2.6b |

## Operating expense total | 3.2b | 4.7b | 3.3b | 3.6b | 4.3b | 3.6b | 3.6b | 3.8b |

## EBIT | 1.7b | (20.0m) | 1.9b | 1.2b | 779.0m | 1.9b | 1.4b | 1.5b |

| 23% | 0% | 24% | 17% | 11% | 24% | 19% | 19% |

## Interest expense | 194.0m | 192.0m | 194.0m | 162.0m | 194.0m | 233.0m | 224.0m | 237.0m |

## Interest income | 21.0m | 15.0m | 13.0m | 20.0m | 27.0m | 10.0m | 34.0m | 21.0m |

## Pre tax profit | 1.6b | (178.0m) | 1.7b | 1.1b | 614.0m | 1.7b | 1.3b | 1.3b |

## Income tax expense | 327.0m | (92.0m) | 316.0m | 348.0m | 139.0m | 193.0m | 310.0m | 214.0m |

## Net Income | 1.2b | (86.0m) | 1.4b | 759.0m | 475.0m | 1.5b | 985.0m | 1.1b |

GBP | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Cash | 4.9b | 3.8b | 3.9b |

## Accounts Receivable | 6.0b | 6.0b | 6.4b |

## Inventories | 5.1b | 5.6b | 5.5b |

## Current Assets | 16.7b | 15.9b | 16.9b |

## PP&E | 10.8b | 10.9b | 11.1b |

## Goodwill | 6.0b | 5.7b | 5.8b |

## Total Assets | 59.1b | 56.4b | 58.1b |

## Accounts Payable | 12.0b | 21.0b | 14.0b |

## Short-term debt | 4.1b | 2.8b | 5.8b |

## Current Liabilities | 19.0b | 26.6b | 22.5b |

## Long-term debt | 14.7b | 14.3b | 20.3b |

## Non-Current Liabilities | 35.1b | 26.3b | 31.9b |

## Total Debt | 18.8b | 17.1b | 26.1b |

## Total Liabilities | 54.1b | 52.9b | 54.4b |

## Common Stock | 1.3b | 1.3b | 1.3b |

## Additional Paid-in Capital | 3.0b | 3.0b | 3.1b |

## Retained Earnings | (5.4b) | (6.5b) | (2.1b) |

## Total Equity | 5.0b | 3.5b | 4.4b |

## Debt to Equity Ratio | 3.8 x | 4.9 x | 6 x |

## Debt to Assets Ratio | 0.3 x | 0.3 x | 0.4 x |

## Financial Leverage | 11.9 x | 16.2 x | 13.3 x |

GBP | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Net Income | 1.1b | 2.2b | 4.0b |

## Depreciation and Amortization | 1.9b | 3.0b | 1.8b |

## Cash From Operating Activities | 6.5b | 6.9b | 8.4b |

## Purchases of PP&E | (1.5b) | (1.5b) | (1.3b) |

## Capital Expenditures | (809.0m) | (657.0m) | (452.0m) |

## Cash From Investing Activities | (1.3b) | (1.4b) | (1.6b) |

## Short-term Borrowings | (919.0m) | (3.2b) | (2.0b) |

## Long-term Borrowings | (18.0m) | (23.0m) | (28.0m) |

## Dividends Paid | (4.8b) | (3.9b) | (3.9b) |

## Cash From Financing Activities | (6.4b) | (6.4b) | (6.4b) |

## Net Change in Cash | (1.2b) | (905.0m) | 479.0m |

## Interest Paid | 732.0m | 781.0m | 766.0m |

## Income Taxes Paid | 1.6b | 1.3b | 1.3b |

## Free Cash Flow | 5.7b | 6.3b | 8.0b |

GBP | Y, 2019 |
---|---|

## EV/EBIT | 76 x |

## EV/CFO | 55 x |

## EV/FCF | 69.9 x |

## Debt/Equity | 11.3 x |

## Debt/Assets | 0.5 x |

## Financial Leverage | 21.4 x |

FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | |
---|---|---|---|---|---|

## Volume of Medicines Produced | 2 b | 1.90 b | 2.30 b | ||

## Vaccines | 833 m | 798 m | 770 m | ||

## Consumer Healthcare Products Produced | 5 b | 6.20 b | 3.80 b | ||

## Vaccine Doses Delivered per Day | 2 m | 2 m | 2 m | ||

## Countries | 100 | 100 | 100 | 100 | 100 |

## Manufacturing Facilities | 57 | 54 | 87 | ||

## Markets | 150 | 150 | 150 | ||

## New Product Launches | 50 | 40 | 30 | ||

## Partners | 1.50 k | 1.50 k | 2 k |

FY, 2018 | |
---|---|

## Water Used (Tankers) | 190 k cubic meters |

## Water Used (Municipal) | 9.23 m cubic meters |

## Water Used (Groundwater) | 3.52 m cubic meters |

## Water Used | 12.94 m cubic meters |

## Wastewater Discharged | 10.20 m cubic meters |

## Waste Generated | 126.30 k tonnes |

## Total Energy Used | 15.20 m GJ |

## Number of Lost Time Accidents | 303 |

## Nonhazardous Waste (Landfilled) | 3.70 k tonnes |

## Hazardous Waste (Landfilled) | 200 tonnes |

## Greenhouse Gas Emissions (Scope 2) | 606 k metric tons of carbon dioxide equivalent |

## Greenhouse Gas Emissions (Scope 1) | 823 k metric tons of carbon dioxide equivalent |

## Greenhouse Gas Emissions (Scope 1 and Scope 2) | 1.43 m metric tons of carbon dioxide equivalent |

## Energy Used from Renewable Energy Sources (Purchased) | 200 k GJ |

## Energy Used from Renewable Energy Sources (On-Site Renewable Energy) | 100 k GJ |

## Energy Used (Steam) | 200 k GJ |

## Energy Used (Purchased Electricity) | 5.80 m GJ |

## Energy Used (Natural Gas) | 7.70 m GJ |

## Energy Used (Fuel and Other) | 400 k GJ |

## Energy Used (Electricity) | 5.90 m GJ |

## Energy Used (Coal) | 200 k GJ |

## Energy Used (Biomass) | 800 k GJ |

## Electricity Used from Renewable Energy Sources, percent | 4.8% |

## Diversion Rate | 77% |

GlaxoSmithKline's employees are reported to be approximately 45% female and 55% male.